ERBB2 and ovarian cancer: In line with this, toxicity was observed in non-human primates after injection of 10 μg/kg FOLR1-TCB24 and in patients with ovarian cancer treated with the first-generation bispecific antibody OC/TR F(ab′)2 targeting FOLR1 and CD340.